IGF2BP1 and hepatocellular carcinoma: Study demonstrates that PRMT3 contributes to oxaliplatin resistance through a mechanism partially reliant on methylating IGF2BP1 at the R452 position. This methylation is crucial for IGF2BP1’s role in stabilizing HEG1 mRNA, an important component of the PRMT3-IGF2BP1 pathway. Additionally, elevated PRMT3 levels may indicate oxaliplatin resistance in hepatocellular carcinoma (HCC) patients. Overall, PRMT3-IGF2BP1-HEG1 pathway serves as a key regulator in oxaliplatin resistance, presenting potential therapeutic targets